FDA Warns About Mix-ups With Maalox Products
Medications Have Different Uses, Active Ingredients
By News Staff
2/23/2010
Maalox Total Relief is an upset stomach reliever and antidiarrheal liquid medication, while traditional Maalox liquid products -- Maalox Advanced Regular Strength and Maalox Advanced Maximum Strength -- are antacids. All three products, which are manufactured by Novartis Consumer Health Inc., are OTC medications.
The active ingredient in Maalox Total Relief is bismuth subsalicylate, which is chemically related to aspirin and may cause harmful side effects similar to those seen with aspirin use, such as gastrointestinal bleeding. The FDA said patients with a history of gastrointestinal ulcer disease or a bleeding disorder should not use it.
Maalox Total Relief also is inappropriate for children and teens recovering from viral infections and individuals who are taking certain medications, including oral antidiabetic drugs, anticoagulants, nonsteroidal anti-inflammatory drugs and other anti-inflammatory drugs.
The traditional Maalox liquid products, including Maalox Advanced Regular Strength and Maalox Advanced Maximum Strength, are antacid products that contain aluminum hydroxide, magnesium hydroxide and simethicone. Those products are used for the relief of acid indigestion, heartburn, sour or upset stomach, and gas.
The FDA said it has received five reports of serious medication errors involving consumers who mistakenly used Maalox Total Relief when they had intended to use one of the traditional Maalox antacid products.
The agency said in a safety announcement that when recommending an OTC medicine, physicians should refer to the product by its full name or use the name of the active ingredient. Physicians also should ensure that patients know the uses of the product prior to purchase.
Physicians are encouraged to report adverse events or medication errors involving Maalox products to the FDA's MedWatch program.
The FDA said Novartis has agreed to change the name of Maalox Total Relief to one that does not include the word "Maalox." The manufacturer also plans to change the product's packaging.
The rebranded product is expected to be available in September. Until then, the FDA is advising consumers to carefully check the labels of all Maalox products to ensure they are selecting the appropriate product to relieve their symptoms.
Novartis also has agreed to conduct an educational campaign regarding the products with outreach to both physicians and consumers, the FDA said.
Misuse of Fingerstick, Similar Devices Linked to Bloodborne Infections
HHS Expands Medicare Coverage of Tobacco Cessation Counseling
More Than 500 Million Eggs Recalled as Investigation Continues
AAFP Joins Court Brief Supporting Vaccine Injury Compensation Program
GAO Report Critical of Genetic Tests Marketed to Consumers
Advisory Panel Rejects FDA Plan for Controlling Opioid Use
FDA Warns Docs, Patients About Unapproved IUDs
Studies Link Vitamin D, Cognitive Ability in Seniors
NFID Initiative Aims to S.T.O.P. Meningitis!
FDA Expert Panel Members Split on Avandia Question
FDA Adds to Leflunomide's Boxed Warning
McNeil Expands Recall List Again
FDA Warns Against Off-Label Use of Malaria Drug
Dietary Guidelines Report Focuses on Obesity
Pertussis Activity Spikes in Several States
AAFP Wants Medicaid Coverage for Quitlines
HHS Launches Multifaceted Health Literacy Plan
FDA to Report on Safety Monitoring Activities
AAFP Recruiting Practices for Smoking Cessation Pilot
Hypertension Well-controlled in Half of U.S. Adults
AMA Delegates Tackle Various Public Health Issues
CDC: One in Five Teens Has Abused Prescription Meds
Report: FDA Needs Overhaul of Food Safety System
IOM Calls for More Scrutiny of Food, Supplement Health Claims
FDA Proposals Would Shed Light on Drug Approval Process
IV Antibiotics, Antiemetic Recalled After Mold Detected
More Children's Medications From Shuttered McNeil Plant Recalled
Severe Liver Injury Tied to Orlistat Prompts Label Revisions
AAFP, Others Urge Ratification of Tobacco Treaty
AAFP Defends USPSTF, Breast Cancer Screening Recs
FDA Investigating McNeil Consumer Healthcare
Encouraging Healthy Lifestyles: A Special Report on Overweight and Obesity
FDA Campaign Cracks Down on Misleading Drug Ads
FDA Forces Device Maker to Recall Infusion Pumps
McNeil Recalls Multiple OTC Infants', Children's Products
FDA Conducting Safety Review of Prostate Cancer Drugs
FDA Offers Guidance on Rosiglitazone Use as Safety Review Continues
